Page 3 - Heart Failure Clinical Guidelines

3

C. Long-Term Follow-up Schedule for Chemotherapy Induced Cardiomyopathy .................................. 17

IX. NEUROMUSCULAR DISORDER ASSOCIATED CARDIOMYOPATHY .......................................................... 18
A. Initial Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy ............. 18
B. Long-Term Medical Management for Neuromuscular Associated Cardiomyopathy ......................... 18

C. Long-Term Follow-up Schedule for Neuromuscular Disorder associated Cardiomyopathy .............. 18

X. MYOCARDITIS .......................................................................................................................................... 19
A. Initial Evaluation for Patient with Possible Myocarditis ..................................................................... 19
B. Long-Term Medical Management for Myocarditis ............................................................................. 19

C. Immunotherapy Management of Myocarditis ................................................................................... 19
D. Long-Term Follow-up Schedule for Myocarditis ................................................................................ 19

XI. MEDICATIONS ........................................................................................................................................ 21
A. ACE-Inhibitors ..................................................................................................................................... 21
B. Carvedilol ............................................................................................................................................ 21

C. Aldactone ............................................................................................................................................ 22
D. Angiotensin Receptor Blockers ........................................................................................................... 22

E. Digoxin................................................................................................................................................. 23
F. Calcium Channel Blockers (NonDihydropyridines) ............................................................................. 23

G. Beta Blockers (other than Carvedilol)................................................................................................. 24
H. Diuretics .............................................................................................................................................. 24